Alectinib for ALK-positive non-small-cell lung cancer – NICE

NICE – National Institute for Health and Care Excellence shared a post on X:

“A targeted treatment option which can help reduce the risk of the cancer returning, has been recommended for people with non-small-cell lung cancer. Alectinib can be used after surgery for those with ALK-positive non-small-cell lung cancer.

Learn more.”

Yvonne Diaz shared the above post on X, adding:

“Great to see this big step forward for those diagnosed with early stage ALK+ lung cancer. Now we need to find lung cancers early & be sure to give everyone biomarker testing. Can we please also share biomarker test results w patients?

So many lung cancers come back.”

Yvonne serves as EY Global Media Relations and Social Media Director, with a team of over 20 professionals across multiple locations. The team supports EY’s global business objectives, brand aspirations, and overall reputation through various media and social media channels. Her background includes leadership roles in external communications and media relations within the financial and media industries.